Resources

When clinical trials enter phase III, they have already demonstrated considerable safety and efficacy. The drug in question has been scrutinized for years and has been overseen by regulatory bodies such as the US Food and Drug Administration (FDA) and institutional review boards (IRBs), groups that monitor and review biomedical research involving human subjects.¹

Lilly believes that higher enrollment in clinical trials, not only those sponsored by Lilly, is a way to enhance cancer care for patients as a whole. Higher enrollment enables more cutting-edge research, which can lead to better cancer care for patients.

At Lilly, we have achieved rapid pipeline growth into diverse modalities and built capabilities to speed new treatments to patients. Unlocking the potential of the 93% of oncology patients in the US who currently do not participate in clinical trials will accelerate cutting-edge research and increase representation in our trials, bringing optimal care to all patients. This can also shorten our trial enrollment timelines and bring optimal care to patients.²

Lilly has been committed to making breakthrough medicines for nearly 150 years, and clinical trials have been an integral part of our work. Alongside helping to boost clinical trial consideration overall, Lilly is working diligently to help discover and develop even more targeted oncology medicines.

The FDA has produced new guidelines regarding clinical trials, streamlining the process and making it easier for referring oncology healthcare professionals. Changes include obtaining data from routine clinical interactions, enhancing integration of clinical research and overall care, capturing results through standardized electronic health record (EHR) systems, and allowing local oncology healthcare professionals to conduct certain procedures that are within the scope of their practice and expertise.³

We are dedicated to making certain tedious aspects of clinical trials—like paperwork—less burdensome while enabling oncology healthcare professionals to receive updates as they so choose. Through this partnership, you can feel empowered to be involved in clinical trials and give patients the high-quality care they deserve. Our dedication to this cause goes beyond just Lilly-sponsored trials, and we will do everything we can to implement these changes across the entire oncology community.

Phase III clinical trials should be considered for all appropriate patients, because trials provide patients the opportunity to receive investigational treatments. Trials also advance science in the oncology community, now and for the future.

No. You will be connected to the most convenient option for you, your patient, and your practice. Try utilizing the Trial Finder to find out more.

Lilly offers tools to help with this issue. Use the Trial Finder to find an appropriate trial for your patients.

According to new FDA guidelines, local oncology healthcare professionals can conduct certain procedures that are within the scope of their practice and expertise (for example, physicians with gastroenterology expertise can perform endoscopies and colonoscopies that might be needed for trial monitoring) so they can still treat patients even when they’re enrolled in a trial.³